Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avoiding G-CSF in Dose-Dense Paclitaxel for Breast Cancer
NCT02698891Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Apr 2016
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in breast cancer, sponsored by Dana-Farber Cancer Institute. Primary endpoint: Rate of Paclitaxel Treatment Completion Within 7 Weeks. Started Apr 2016; status: completed.
02
Drugs
paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02698891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02698891.